(Andecaliximab)Biosimilar Reference Antibody-GS40025

货号：GS40025

Andecaliximab is a humanized IgG4 monoclonal antibody designed as a specific inhibitor of matrix metalloproteinase-9 (MMP-9). It was developed as a potential therapeutic agent for inflammatory diseases and cancer, with clinical trials primarily focusing on ulcerative colitis and gastric/gastroesophageal junction adenocarcinoma. The antibody functions by allosterically inhibiting the enzymatic activity of MMP-9, aiming to reduce tissue degradation, modulate the tumor microenvironment, and decrease inflammation. Despite advancing to Phase III trials in combination with chemotherapy for gastric cancer, its development was discontinued after the trial did not meet its primary endpoint of improving overall survival.